



# Investor Presentation

May 2026



# Disclaimer & Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight. Such statements may include, without limitation, statements regarding (i) adoption trends and projections regarding the future volume of cataract surgical procedures and related revenue and the role of premium IOLs therein, (ii) estimates of RxSight’s addressable market opportunity and related growth, in the U.S. and globally, (iii) the efficacy of RxSight’s mechanisms and procedures, (iv) the performance of other premium and conventional IOLs compared to RxSight’s, (v) the number of patients eligible for LAL procedures, (vi) revenue associated with LAL procedures and the premium IOL market, (vii) statements regarding our future financial or business performance, (viii) the timing and success of our development and commercialization of our products, (ix) the continued acceptance of our products in the marketplace and our competitive positioning, (x) 2025 LDD installed base, LAL units sold and total revenue; (xi) anticipated continued growth based on RxSight adjustable innovation, and (xii) RxSight’s plans to enter international markets.

This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this presentation from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.

More details about these and other risks that may impact RxSight’s business are described in the company’s press release issued on May 6, 2026, and under the heading “Risk Factors” in Part II, Item 1A of RxSight’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on May 6, 2026, as well as in subsequent filings with the SEC, which are available on the SEC’s website at [www.sec.gov](http://www.sec.gov). RxSight cautions you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. RxSight does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.



## OUR VISION

Transform cataract surgery outcomes via the power of **adjustability**

# Long-Term Innovation Validated by Clinical and Commercial Adoption

**30** Years since the concept of Adjustability



**20** Years since early clinical development




**10** Years since completion of Phase 3 (FDA)




**Proven | Adopted | Trusted**

# The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision



Other Lenses

LAL eyes have  
**14.5 X**  
better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl  $\leq 0.50$  D)<sup>1</sup>



LAL

1. Data on file - RxSight Post-Approval Study

# Adjustability is Becoming a Foundation of Premium Outcomes

## Adjustability Offers:

- Targeted refractive accuracy
- Customization to patient lifestyle
- High patient satisfaction and confidence



# Growing Data Set and Clinical Consensus

## Real world data from over 3,000 eyes <sup>1</sup>

ACCURACY

**>94%**

+/- MRSE <sup>1</sup>

BINOCULAR OUTCOMES

**>90%**

20/25 distance and J2 near without glasses <sup>1</sup>

## LAL Customer Survey

**90%**

believe LAL provides highest quality of vision <sup>2</sup>

**79%**

would select for their own premium IOL surgery (vs 11% for multifocal and 7% EDOF) <sup>2</sup>

1. RxSight Data on File: PMCS-002  
2. 2025 RxSight Customer Survey



# Adjustability Drives Superior Practice Economics

Boosting profitability through premium IOL adoption

## Expand the Premium Market

Data shows 40% of LAL patients would have otherwise chosen a standard, non-premium lens.<sup>1</sup>

## Command a Premium Price

Patients demonstrate a high willingness to pay for customized quality, supporting a significant price premium over fixed alternatives.

## Unify the Care Team

Enables both surgeons and optometrists to actively participate in and benefit from the premium IOL segment.

# \$2,064<sup>1</sup>




Average additional practice net revenue per LAL implanted



1. Haffey & Company 2024 Economic Study of LAL Users

# Historical Trends

A well-established commercial platform validated by a large installed base



# First Quarter 2026 Results

**\$30.9M**

Total Company  
Revenue

**27,472**

LALs Sold

**1,154**

LDD Installed  
Base

**76.1%**

Gross Margin

**\$218M**

Cash, Cash  
Equivalents &  
ST Investments



# Driving Growth Through Utilization Expansion and Surgeon Access

## Utilization Growth (Same-Store Sales)

- Increased procedures per trained surgeon
- Driven by training, confidence, and patient demand
- Focus on both high- and low-volume surgeons




## Expanding Surgeon Access Through Multiple Paths

- New LDD placements in additional practices
- Incremental surgeons within existing LDD sites
- Open-access model extending reach beyond in-office LDDs



# Making Personalized Cataract Surgery Faster, Simpler, and More Precise

Future Innovation



# A Large, Underpenetrated Global Premium Opportunity

1X



4X


Key OUS markets make up >80% of global procedures with growing procedure potential<sup>1</sup>

## Progress to Date

- Team buildout and regulatory

## Next Steps

- Focus on initial target markets
- KOL development, early installs



1. Market Scope 2025 Premium Cataract Surgery Market Report, October 2025

# Adjustability Wins Long-Term

**RxSight offers the only Adjustable IOL**

## **Market & Platform Strength**

Large, growing market  
Large, stable installed base  
Only adjustable IOL

## **Execution & Growth Optionality**

Structural improvements in commercial execution  
International opportunity  
Pipeline opportunities

## **Revenue & Margin Expansion**

Utilization-led growth  
Recurring LAL mix improves gross margins

## **Financial Strength**

Strong balance sheet to fund growth



**Thank You**

